Leap Therapeutics
Cambridge, US · Delaware corporation · 1 known investors
Oncology company developing targeted and immuno-oncology therapeutics; lead candidate DKN-01 targets the DKK1 protein.
Founders & leadership
CM
Christopher MirabelliChief Executive Officer, President and Director
AL
Augustine LawlorChief Operating Officer
DO
Douglas OnsiChief Financial Officer
TD
Thomas DietzNamed on SEC filing
JL
Joseph LoscalzoNamed on SEC filing
NM
Nissim MashiachNamed on SEC filing
WL
William LiNamed on SEC filing
Board
JL
John LittlechildBoard director
JC
James CavanaughBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$95.2M disclosed across 2 rounds · 2017–2023
▶$77.2MraisedMar 2023 · 121 investors · PharmaceuticalsRule 506(b)
▶$77.2MraisedMar 2023 · 121 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph LoscalzoDirector
- Christian RichardDirector
- Christine GranfieldExecutive Officer
- Patricia MartinDirector
- Nissim MashiachDirector
- Christopher K. MirabelliDirector
- Cynthia SirardExecutive Officer
- James CavanaughDirector
- Richard SchilskyDirector
- Augustine LawlorExecutive Officer
- William LiDirector
- Thomas DietzDirector
- Mark O'MahonyExecutive Officer
- Douglas E. OnsiExecutive Officer, Director
- Offering amount
- $77.2M
- Amount sold
- $77.2M
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedNov 2017 · 14 investors · BiotechnologyRule 506(b)
▶$18MraisedNov 2017 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John LittlechildDirector
- Thomas DietzDirector
- Joseph LoscalzoDirector
- Nissim MashiachDirector
- James CavanaughDirector
- Douglas OnsiExecutive Officer
- Christopher MirabelliExecutive Officer, Director
- William LiDirector
- Augustine LawlorExecutive Officer
- Offering amount
- $18M
- Amount sold
- $18M
- Sales commissions
- $400K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Leap Therapeutics do?
- Oncology company developing targeted and immuno-oncology therapeutics; lead candidate DKN-01 targets the DKK1 protein.
- Who founded Leap Therapeutics?
- Leap Therapeutics was founded by Christopher Mirabelli, Augustine Lawlor.
- Who are Leap Therapeutics's investors?
- Leap Therapeutics's investors include Torrey Pines Investment.
- How much funding has Leap Therapeutics raised?
- Leap Therapeutics has disclosed $95.2M raised across 2 rounds.
- Where is Leap Therapeutics headquartered?
- Leap Therapeutics is headquartered in Cambridge, US.